Discounted Cash Flow (DCF) Analysis Unlevered

Orchard Therapeutics plc (ORTX)

$0.4851

+0.00 (+0.48%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 0.4851 | undervalue

Operating Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 0.4,851
Beta 0.769
Diluted Shares Outstanding 123.96
Cost of Debt
Tax Rate -0.58
After-tax Cost of Debt 9.11%
Risk-Free Rate
Market Risk Premium
Cost of Equity 7.326
Total Debt 27.40
Total Equity 60.13
Total Capital 87.53
Debt Weighting 31.30
Equity Weighting 68.70
Wacc

Build Up Free Cash

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate -0.13%-0.42%1.35%0.48%-0.58%0.14%0.14%0.14%0.14%0.14%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure -1.56-4.03-4.37-12.67-2.35-----
UFCF ----------
WACC
PV UFCF -----
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 7.88
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -28.51
Equity Value -
Shares Outstanding 123.96
Equity Value Per Share -